Mineralys Therapeutics (MLYS) completed enrollment in its Phase 2 EXPLORE-OSA trial of lorundrostat in participants with moderate-to-severe OSA and hypertension. Now that participant enrollment is complete, the Company anticipates analyzing and reporting top-line results of the EXPLORE-OSA trial in the first quarter of 2026. If the trial is successful, the Company believes these data will complement the previously announced positive topline data from its EXPLORE-CKD trial. Demonstrating positive results in these two patient populations would continue to expand the opportunity for lorundrostat in treating hypertension patients with these comorbidities.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- Insiders Pour Millions into These 2 Stocks — Goldman Sachs Backs the Move
- Mineralys Therapeutics falls -4.9%
- Mineralys Therapeutics price target raised to $50 from $26 at Wells Fargo
- Buy Rating for Mineralys Therapeutics, Inc. Driven by Promising Phase 3 Results and Strong Financial Position
- Buy Rating Affirmed for Mineralys Therapeutics Due to Promising Hypertension Drug Data and Market Position